These include diffuse astrocytoma, MYB- or MYBL1-altered; diffuse low-grade glioma, MAPK pathway-altered; polymorphous low-grade neuroepithelial tumor of the young (BRAF mutations and FGFR2 fusions); and infant-type hemispheric glioma (alterations in NTRK, ROS1, ALK, or MET) [112,113]. This evidence concerns the gene MET and diffuse astrocytoma.